LGALS3 and idiopathic pulmonary fibrosis: GB0139 (also known as TD139), is a potent thiodigalactoside inhibitor of galectin-3 [24], and a phase 1/2a trial (ClinicalTrials.gov identifier: NCT02257177) evaluated the pharmacokinetic (PK) and pharmacodynamic (PD) profile of GB0139 in healthy individuals and patients with idiopathic pulmonary fibrosis (IPF).